Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives
and Recommendations

J 2022

Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations

BALIAKAS, Panagiotis, Blanca ESPINET, Clemens MELLINK, Marie JAROŠOVÁ, Anastasia ATHANASIADOU et. al.

Základní údaje

Originální název

Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations

Autoři

BALIAKAS, Panagiotis (garant), Blanca ESPINET, Clemens MELLINK, Marie JAROŠOVÁ (203 Česká republika, domácí), Anastasia ATHANASIADOU, Paolo GHIA, Arnon P KATER, David OSCIER, Claudia HAFERLACH a Kostas STAMATOPOULOS

Vydání

HemaSphere, Philadelphia, Lippincott Williams & Wilkins, 2022, 2572-9241

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.600

Kód RIV

RIV/00216224:14110/22:00129675

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1097/HS9.0000000000000707

UT WoS

000776250000005

Klíčová slova anglicky

Chronic Lymphocytic Leukemia; Cytogenetics

Štítky

14110212, 14110323, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 8. 2022 12:11, Mgr. Tereza Miškechová

Anotace

V originále

Mounting evidence underscores the clinical value of cytogenetic analysis in chronic lymphocytic leukemia (CLL), particularly as it allows the identification of complex karyotype, that has recently emerged as a prognostic and potentially predictive biomarker. That said, explicit recommendations regarding the methodology and clinical interpretation of either chromosome banding analysis (CBA) or chromosome microarray analysis (CMA) are still lacking. We herein present the consensus of the Cytogenetic Steering Scientific Committee of ERIC, the European Research Initiative on CLL, regarding methodological issues as well as clinical interpretation of CBA/CMA and discuss their relevance in CLL. ERIC considers CBA standardized and feasible for CLL on the condition that standards are met, extending from the use of novel mitogens to the accurate interpretation of the findings. On the other hand, CMA, is also standardized, however, robust data on its clinical utility are still scarce. In conclusion, cytogenetic analysis is not yet mature enough to guide treatment choices in CLL. That notwithstanding, ERIC encourages the wide application of CBA, and potentially also CMA, in clinical trials in order to obtain robust evidence regarding the predictive value of specific cytogenetic profiles towards refining risk stratification and improving the management of patients with CLL.

Návaznosti

NU20-08-00314, projekt VaV

Název: Single cell analýza: moderní nástroj pro studium klonální evoluce u pacientů s chronickou lymfocytární leukémií s vysokým rizikem (Akronym: Single cell analysis of CLL cells)

Investor: Ministerstvo zdravotnictví ČR, Single cell analysis: a modern tool to study clonal evolution in high-risk patients with chronic lymphocytic leukemia, Podprogram 1 - standardní

NU21-08-00237, projekt VaV

Název: Pokročilé sekvenační metody pro analýzu strukturních přestaveb nádorového genomu

Investor: Ministerstvo zdravotnictví ČR, Pokročilé sekvenační metody pro analýzu strukturních přestaveb nádorového genomu, Podprogram 1 - standardní

NV19-03-00091, projekt VaV

Název: Komplexní prognostický a prediktivní panel pro pacienty s chronickou lymfocytární leukémií: nástroj sekvenování nové generace vhodný pro klinickou praxi i studium genetického pozadí průběhu choroby

Investor: Ministerstvo zdravotnictví ČR, Comprehensive prognostic and predictive panel for chronic lymphocytic leukemia: a next-generation sequencing tool suitable for clinical practice and study of genetic architecture behind the disease progress

Citovat

BALIAKAS, Panagiotis, Blanca ESPINET, Clemens MELLINK, Marie JAROŠOVÁ, Anastasia ATHANASIADOU, Paolo GHIA, Arnon P KATER, David OSCIER, Claudia HAFERLACH a Kostas STAMATOPOULOS. Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations. HemaSphere. Philadelphia: Lippincott Williams & Wilkins, 2022, roč. 6, č. 4, s. 1-7. ISSN 2572-9241. Dostupné z: https://dx.doi.org/10.1097/HS9.0000000000000707.

@article{2211017,
   author = {Baliakas, Panagiotis and Espinet, Blanca and Mellink, Clemens and Jarošová, Marie and Athanasiadou, Anastasia and Ghia, Paolo and Kater, Arnon P and Oscier, David and Haferlach, Claudia and Stamatopoulos, Kostas},
   article_location = {Philadelphia},
   article_number = {4},
   doi = {http://dx.doi.org/10.1097/HS9.0000000000000707},
   keywords = {Chronic Lymphocytic Leukemia; Cytogenetics},
   language = {eng},
   issn = {2572-9241},
   journal = {HemaSphere},
   title = {Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations},
   url = {https://journals.lww.com/hemasphere/Fulltext/2022/04000/Cytogenetics_in_Chronic_Lymphocytic_Leukemia__ERIC.6.aspx},
   volume = {6},
   year = {2022}
}

TY  - JOUR
ID  - 2211017
AU  - Baliakas, Panagiotis - Espinet, Blanca - Mellink, Clemens - Jarošová, Marie - Athanasiadou, Anastasia - Ghia, Paolo - Kater, Arnon P - Oscier, David - Haferlach, Claudia - Stamatopoulos, Kostas
PY  - 2022
TI  - Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations
JF  - HemaSphere
VL  - 6
IS  - 4
SP  - 1-7
EP  - 1-7
PB  - Lippincott Williams & Wilkins
SN  - 25729241
KW  - Chronic Lymphocytic Leukemia
KW  - Cytogenetics
UR  - https://journals.lww.com/hemasphere/Fulltext/2022/04000/Cytogenetics_in_Chronic_Lymphocytic_Leukemia__ERIC.6.aspx
N2  - Mounting evidence underscores the clinical value of cytogenetic analysis in chronic lymphocytic leukemia (CLL), particularly as it allows the identification of complex karyotype, that has recently emerged as a prognostic and potentially predictive biomarker. That said, explicit recommendations regarding the methodology and clinical interpretation of either chromosome banding analysis (CBA) or chromosome microarray analysis (CMA) are still lacking. We herein present the consensus of the Cytogenetic Steering Scientific Committee of ERIC, the European Research Initiative on CLL, regarding methodological issues as well as clinical interpretation of CBA/CMA and discuss their relevance in CLL. ERIC considers CBA standardized and feasible for CLL on the condition that standards are met, extending from the use of novel mitogens to the accurate interpretation of the findings. On the other hand, CMA, is also standardized, however, robust data on its clinical utility are still scarce. In conclusion, cytogenetic analysis is not yet mature enough to guide treatment choices in CLL. That notwithstanding, ERIC encourages the wide application of CBA, and potentially also CMA, in clinical trials in order to obtain robust evidence regarding the predictive value of specific cytogenetic profiles towards refining risk stratification and improving the management of patients with CLL.
ER  -

BALIAKAS, Panagiotis, Blanca ESPINET, Clemens MELLINK, Marie JAROŠOVÁ, Anastasia ATHANASIADOU, Paolo GHIA, Arnon P KATER, David OSCIER, Claudia HAFERLACH a Kostas STAMATOPOULOS. Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations. \textit{HemaSphere}. Philadelphia: Lippincott Williams \&{} Wilkins, 2022, roč.~6, č.~4, s.~1-7. ISSN~2572-9241. Dostupné z: https://dx.doi.org/10.1097/HS9.0000000000000707.

Podrobný výpis o publikaci